Calcineurin inhibitors are used to stop the working of calcineurin, by binding to protein cells called immunophilins. Calcineurin inhibitors are used topically and systemically to treat various inflammatory skin diseases.
Based on diseases condition, the global calcineurin inhibitor drugs market can be segmented into eczema, psoriasis, ulcerative colitis, and others. The eczema segment is projected to expand at a significant pace during the forecast period, attributed to high prevalence of eczema across the globe. In terms of drug type, the global market can be classified into pimecrolimus, tacrolimus, ciclosporin, tacrolimus, and others. The tacrolimus segment is anticipated to expand at a high CAGR from 2018 to 2026, as most doctors prefer to use tacrolimus because it penetrates the cutaneous barrier of the skin to a much greater extent, resulting in effective outcome.
Based on dosage form, the global calcineurin inhibitor drugs market can be bifurcated into topical and oral. The topical segment is likely to expand at a rapid pace during the forecast period, because topical form of drug does not cause skin atrophy and absorption through the skin is minimal. In terms of distribution channel, the global market can be divided into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment is expected to expand at a high CAGR from 2018 to 2026, as skin diseases are mostly treated in independent clinics such as skin centers and patients feel convenient to purchase drugs through retail pharmacies. Moreover, usage of the drug does not require strict supervision.
Rise in prevalence of atopic dermatitis is a major factor fueling the global calcineurin inhibitor drugs market. Moreover, rise in awareness and availability of new formulation drugs are projected to drive the market during the forecast period. However, side effects of the drugs such as gastrointestinal disturbances, nephrotoxicity, and skin burning are projected to restrain the market in the next few years.
Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=46413
In terms of region, the global calcineurin inhibitor drugs market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. The region is projected to account for a significant share of the global market during the forecast period, due to rise in prevalence of atopic dermatitis in children. According to a report published in the journal Dermatology Clinics 2017, about 6% to 12% children were affected with atopic dermatitis in the U.S. Rosacea diseases is a major concern in countries in Europe.
According to the Journal of the European Academy of Dermatology and Venereology, prevalence of rosacea skin disease in Germany was 12% in 2016 and is likely to increase in the near future. This factor is projected to drive the calcineurin inhibitor drugs market in Europe. Rise in prevalence of psoriasis, and increase in awareness about psoriasis among health care providers and society in the region are anticipated to fuel the growth of the market in Asia Pacific during the forecast period. Rise in prevalence of skin diseases such as infantile acropustulosis, psoriasis, and papular urticaria in Central Africa is likely to augment the calcineurin inhibitor drugs market in Middle East & Africa 2018 to 2026.
Key players operating in the global calcineurin inhibitor drugs market are Novartis AG, AbbVie Inc., Astellas Pharma, and Pfizer, Inc., among others.